Biomarker Testing for Autoimmune Rheumatic Disease Lab Benefit Program (LBM)
This reimbursement policy governs coverage and payment for biomarker laboratory testing (e.g., ANA, ENA, RF, anti-CCP, dsDNA, selected myositis and disease‑specific antibodies) for evaluation and management of systemic autoimmune rheumatic diseases for EmblemHealth members.
Coverage Criteria 1, 2, & 3 were edited for clarity on allowed frequency of biomarker testing.
Added aisle@ DX Disease Activity Index and Early Sjogren's Syndrome Profile to the list of proprietary panels not meeting coverage criteria.
Policy content was transferred to individual company-branded template.
Lab Benefit Program (LBM) expanded to cover EmblemHealth HMO/PPO (Non-City), Commercial, Medicare and Medicaid plans effective 10/1/2024.
Applicable CPT/HCPCS codes 86200, 86430 & 86431 were added; CPT code 81490 was previously added to the procedure code table.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.